cyclodextrin

(redirected from Beta-cyclodextrins)
Also found in: Dictionary, Medical, Wikipedia.

cyclodextrin

[¦sī·klō′dek·strən]
(biochemistry)
Mentioned in ?
References in periodicals archive ?
These studies led to the hypothesis that many of the 21 hydroxyl groups on beta-cyclodextrin molecules could be derivatrzed to form a closely related family of analogous chemical compounds containing both polymerizable groups and hydrophilic ionizable ligand (substrate-binding) groups, each attached via hydrolyticaliy-stablc ether-linkages.
The objective was to attach, by means of hydrolytically stable ether linkages, several polymerizable groups and hydrophilic carboxylate-terminated ligand groups per molecule of beta-cyclodextrin.
Beta-cyclodextrin (BCD) is a cyclic oligosaccharide that consists of seven glucopyranose units, linked by alpha 1-4 glycoside linkages.
2 Computer Modeling of Beta-Cyclodextrin, Reagents, Products and Formulations
0 g of the crystallized and dried beta-cyclodextrin (Table 1), 0.
Materials used in the synthesis of a family of polymerizable cyclodextrin derivatives Acronym Chemical Lot Manufacturer BCD beta-cyclodextrin G American 6020-42 Maize-Products USP Co.
Billerica, MA, USA) to provide the number and type of groups that became attached to the beta-cyclodextrin molecules.
The spectra were compared with available literature information depicting spectra of beta-cyclodextrin and some of its derivatives (22), (23).
Prices for gamma-cyclodextrin have been about 100-fold greater than those of beta-cyclodextrin over the past 10 years, but they are drifting downward with prospects of market competition, according to an industry spokesperson.
Currently, worldwide sales of beta-cyclodextrin are estimated at 2 million pounds, mostly for encapsulating food additives in Japan.
today announced the signing of a licensing agreement granting Daiichi worldwide rights to CyDex's CAPTISOL(R) sulfobutylether beta-cyclodextrin (SBE-beta-CD) drug delivery technology for an undisclosed Daiichi compound.
NYSE: AGN), today announced the signing of an agreement granting Allergan an option to license worldwide exclusive rights to CyDex's CAPTISOL(R) sulfobutylether beta-cyclodextrin drug delivery technology for specific ophthalmic uses.